A61P 25 - Drugs for disorders of the nervous system

Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
11/2006
11/08/2006	CN1283250C Stabilized formulations of 6-hydroxy-3-(4-[piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene and salts thereof
11/07/2006	US7132570 Method for the production of crystalline forms and crystalline forms of optical enantiomers of modafinil
11/07/2006	US7132568 beta-amino amides; treating degenerative dementias characterized by beta-amyloid deposits in the brain, especially Alzheimer's Disease
11/07/2006	US7132551 Piperidine and azepine derivatives; anxiolytic, analgesic, antidepressant, antiemetic, antiinflammatory, and hypotensive agents; sexual and psychological disorders; Alzheimers, Parkinsons, Lesche-Nyhane, Wilsons, and Tourettes syndrome
11/07/2006	US7132537 Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
11/07/2006	US7132521 Molecular regulatory circuits to achieve sustained activation of genes of interest by a single stress
11/07/2006	US7132457 Adamantane derivatives
11/07/2006	US7132443 Fluoropyrrolidines as dipeptidyl peptidase inhibitors
11/07/2006	US7132439 Bis-benzimidazoles and related compounds as potassium channel modulators
11/07/2006	US7132438 Benzimidazole derivatives
11/07/2006	US7132436 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
11/07/2006	US7132434 N-[(3S)-1-hydroxy-2-oxopyrrolidinyl]-N-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-4-sulfonamide or derivatives to treat Respiratory system disorders; arthritis, and bone disorders
11/07/2006	US7132433 Use of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4- piperidinemethanol or its prodrug in the treatment of behavioral or psychological symptoms associated with a disease
11/07/2006	US7132429 Sulfonamido ether substituted imidazoquinolines
11/07/2006	US7132422 An aromatic-oxy-alkyleneamine derivative, useful for treating neuropathic pain
11/07/2006	US7132414 Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation
11/07/2006	US7132408 Composition and method for inhibiting platelet aggregation
11/07/2006	US7132396 Compositions which can be used for regulating the activity of parkin
11/07/2006	US7132285 Extracorporeal treatment of the patient's blood cells to induce apoptosis and administration of the apoptotic bodies and/or cells to patient; T-cell- mediated and inflammatory disorders
11/07/2006	US7132261 Nuclear localization peptides for estrogens; antitumor agents; anticarcinogenic agents; hormone replacement therapy; bradycardial agents
11/07/2006	US7132259 nucleic acids encoding neurotoxin polypeptides with a functional binding domain, translocation domain, a therapeutic domain and a non-native protease cleavage site for cleavage in vitro following expression as a single chain; for biosynthesis of botulinum neurotoxins in host cells
11/07/2006	US7132248 Uses of galanin GALR2 receptors
11/07/2006	US7132118 Superoxide dismutase-containing cucumber extract coated and/or microencapsulated in a fat-soluble agent based on a fatty substance can be used by the topical or oral route; antiallergens; sunscreen agents; foods; drugs; cosmetics
11/07/2006	US7132112 Mixture with alcohol carrier; administering to drug nose mucous membrane; side effect reduction
11/07/2006	CA2416879C Methods of treating cancer and the pain associated therewith using endothelin antagonists
11/07/2006	CA2375093C Delivery system for oral care compositions comprising organosiloxane resins using a removable backing strip
11/07/2006	CA2274093C Substituted pyrimidinone and pyridinone compounds and their use
11/07/2006	CA2261802C Use of xanomeline for treating bipolar disorder
11/07/2006	CA2260943C Formulation of 5-ht agonists
11/07/2006	CA2252515C Pharmaceutical compositions for prevention and treatment of central nervous system disorders
11/07/2006	CA2244777C 2,3-benzodiazepine derivatives and their use as ampa-receptor inhibitors
11/02/2006	WO2006116630A2 Method for use of acetyl-l-carnitine ( alcar) for treatment of depressive disorders in humans
11/02/2006	WO2006116401A1 C-5 substituted quinazolinone derivatives as selective estrogen receptor beta modulators
11/02/2006	WO2006116355A1 Ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders
11/02/2006	WO2006116221A2 Therapeutic combinations for the treatment or prevention of psychotic disorders
11/02/2006	WO2006116218A1 Crystal forms of {[(2r)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride
11/02/2006	WO2006116171A1 Treatment of pain
11/02/2006	WO2006116170A1 Dihydrobenzofuran derivatives and uses thereof
11/02/2006	WO2006116165A1 Chromane and chromene derivatives and uses thereof
11/02/2006	WO2006116158A1 Benzodioxane and benzodioxolane derivatives and uses thereof
11/02/2006	WO2006116151A1 Benzofuranyl alkanamine derivatives and uses thereof as 5-ht2c agonists
11/02/2006	WO2006116150A1 Dihydrobenzofuran derivatives and uses thereof
11/02/2006	WO2006116149A1 New therapeutic combianations for the treatment or prevention of depression
11/02/2006	WO2006116136A1 Dihydrobenzofuran derivatives and uses thereof
11/02/2006	WO2006115452A1 Use of pyrazolyl-pyrimidine derivatives in the treatment of pain
11/02/2006	WO2006115304A1 Agent for treating neuropathic pain
11/02/2006	WO2006115302A1 Therapeutic agent for neuropathic pain
11/02/2006	WO2006115285A1 Pharmaceutical composition
11/02/2006	WO2006115247A1 HIGHLY SELECTIVE Rho-KINASE INHIBITOR
11/02/2006	WO2006115188A1 Heterocyclic compound
11/02/2006	WO2006115154A1 Crystal polymorphism of 4’-{2-[(1s,2r)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethylamino]ethoxy}-3-isopropyl-3’,5’-dimethylbiphenylcarboxylic acid hydrochloride
11/02/2006	WO2006115134A1 Novel benzofuran derivative, pharmaceutical composition comprising the same, and use of the derivative or composition
11/02/2006	WO2006115026A1 Humanin receptor or humanin-like polypeptide receptor
11/02/2006	WO2006114790A2 Polar lipid mixtures, their preparation and uses
11/02/2006	WO2006114707A1 Amino acid derivatives
11/02/2006	WO2006114706A1 Triazole derivatives as vasopressin antagonists
11/02/2006	WO2006114666A1 SUBSTITUTED ARYL 1,4-PYRAZlNE DERIVATIVES
11/02/2006	WO2006114467A1 Use of hydroxytyrosol in the prevention and treatment of cerebral ischemic stroke
11/02/2006	WO2006114400A1 Novel oxadiazole derivatives and their medical use
11/02/2006	WO2006114372A1 Acetyl l-carnitine for preventing painful peripheral diabetic neuropathy
11/02/2006	WO2006114322A1 Use of tlr and/or nod2 ligands for producing a medicament for treating a disease of the central nervous system
11/02/2006	WO2006114274A1 Oxazole and thiazole compounds and their use in the treatment of pge2 mediated disorders
11/02/2006	WO2006114264A1 Acetylene derivatives
11/02/2006	WO2006114262A1 Acetylene derivatives
11/02/2006	WO2006114093A1 Pro-drugs of n-thiazol-2yl-benzamide derivatives
11/02/2006	WO2006092032A3 PHARMACEUTICAL COMPOSITIONS CONTAINING 1-METHYL-3,6,7,8-TETRAHYDROPIRAZOLO[3,4-b]PIRROLO[4,3-d]PYRIDINE-6,8-DIONE DERIVATIVES, USE, AND PROCESS FOR PREPARING THEM
11/02/2006	WO2006084854A3 [1,2,4]-dithiazoli(di)ne derivatives, inducers of gluthathione-s-transferase and nadph quinone oxido-reductase, for prophylaxis and treatment of adverse conditions associated with cytotoxicity in general and apoptosis in particular
11/02/2006	WO2006070290A3 Agents and methods for early diagnosis and monitoring of alzheimer's disease and other neurological disorders
11/02/2006	WO2006069808A3 Nitro-substituted phenyl-piperazine compounds, their preparation and use in medicaments
11/02/2006	WO2006059149A8 Arylsulfonylnaphthalene derivatives as 5ht2a antagonists
11/02/2006	WO2006033007A3 Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
11/02/2006	WO2005107748A3 Method of tonic treatment with oxyphenbutazone derivatives
11/02/2006	US20060248605 Beta-amyloid peptide-binding proteins and polynucleotides encoding the same
11/02/2006	US20060248601 Modification of organelle metabolism by unc-51-like kinases roma1 or 2tm proteins
11/02/2006	US20060247451 Crystalline base of citalopram
11/02/2006	US20060247448 zearalenone-like macrolides, used to to inhibit nuclear factor kappa-beta (NF- kappa B) activation, as sucnscreen agents and in the treatment of inflammatory or autoimmune disorders and disorders involving malignancy or increased angiogenesis
11/02/2006	US20060247439 Mchir antagonists
11/02/2006	US20060247293 suppressing death of optic nerve cells during ocular hypertension in patient with glaucoma via administering 3-methyl-1-phenyl-2-pyrazolin-5-one; drops, sustained release formulations
11/02/2006	US20060247290 Derivatives of dioxan-2-alkyl carbamates, preparation thereof and application thereof in therapeutics
11/02/2006	US20060247268 N-sulfonylaminothiazole
11/02/2006	US20060247261 Pyrimidine compounds
11/02/2006	US20060247252 Augmented cognitive training
11/02/2006	US20060247240 Method of treatment and/or prevention of brain, spinal or nerve injury
11/02/2006	US20060247227 Substituted piperidines as histamine h3 receptor ligands
11/02/2006	US20060247223 Non-imidazole alkylamines as histamine H3- receptor ligands and their therapeutic applications
11/02/2006	US20060247203 Freeze-dried preparation containing methylcobalamin and process for producing the same
11/02/2006	US20060246110 Sustained release pharmaceutical composition
11/02/2006	US20060246101 Oral controlled release formulations
11/02/2006	US20060246085 Methods for manipulating satiety
11/02/2006	US20060246066 Cleavable reagents for specific delivery to disease sites
11/02/2006	US20060246062 Anti-ccr4 antibodies and methods of use therefor
11/02/2006	US20060246047 Peptide wirh apoptosis-inhibiting activity
11/02/2006	US20060246042 Cells, culture methods, and their use in autologous transplantation therapy
11/02/2006	US20060246039 Growth differentiation factor-7
11/02/2006	US20060246038 Method of treating a disorder by suicide gene therapy
11/02/2006	US20060246012 Delivery of physiologically active compounds through an inhalation route
11/02/2006	US20060246011 Delivery of diphenhydramine through an inhalation route
11/02/2006	US20060243276 Methods for treating rhinitis and conjunctivitis
11/02/2006	EP1717251A2 Methods of therapy for B-cell malignancies using human anti-CD40 antibodies
11/02/2006	EP1717250A1 Monoclonal antibody and use thereof

1 ... 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 ... 1833